Literature DB >> 23067268

Immune responses against Helicobacter pylori in gastric cancer patients and in risk groups for gastric cancer.

Jenni Adamsson1, Samuel B Lundin, Lars-Erik Hansson, Henrik Sjövall, Ann-Mari Svennerholm.   

Abstract

BACKGROUND: It has previously been reported that weak serum IgG but elevated IgA antibody responses against H. pylori may be associated with risk of gastric cancer (GC) development. To search for potential immunologic markers for GC, we analyzed antibody responses against H. pylori in risk groups of cancer development.
MATERIAL AND METHODS: Sera and stomach biopsies collected from H. pylori-infected GC patients as well as from patients with gastric ulcer (GU), atrophic gastritis, intestinal metaplasia (IM) and duodenal ulcer and from H. pylori-infected control subjects without atrophy or IM, and in addition from H. pylori-negative subjects were analyzed for IgG and IgA antibodies against three different H. pylori antigen preparations, that is, membrane protein (MP), urease, and CagA.
RESULTS: We observed an increased serum IgA/IgG titer ratio against H. pylori anti-MP in GC and GU patients, and against CagA in Hp-infected GC patients and risk groups. Female patients with GC had a higher serum anti-MP IgA/IgG titer ratio and a higher proportion of poorly differentiated cancer compared with male patients. As earlier observed, the non-tumorous mucosa of H. pylori-infected GC patients contained considerably lower levels of total IgA and H. pylori-specific IgA compared with H. pylori-infected controls. Similarly, we observed decreased specific mucosal anti-MP IgA response in patients with IM.
CONCLUSION: We observed several differences in local and systemic immunologic responses against H. pylori in H. pylori-infected GC patients and putative GC risk group patients compared with H. pylori-infected controls. These findings may be of importance in efforts to identify risk groups of GC or early stages of GC.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067268     DOI: 10.1111/j.1523-5378.2012.00991.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  5 in total

1.  MicroRNA-99b promotes Helicobacter pylori-induced autophagyand suppresses carcinogenesis by targeting mTOR.

Authors:  Liu Yang; Cong Li; Yujie Jia
Journal:  Oncol Lett       Date:  2018-08-06       Impact factor: 2.967

2.  Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients.

Authors:  Stefan Sorin Arama; Catalin Tiliscan; Cristina Negoita; Alexandru Croitoru; Victoria Arama; Carmen Marina Mihai; Florinel Pop; Amit Garg
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

Review 3.  Diagnosis of Helicobacter pylori: Changes towards the Future.

Authors:  Behnam Kalali; Luca Formichella; Markus Gerhard
Journal:  Diseases       Date:  2015-06-29

4.  Gastric cancer progression associated with local humoral immune responses.

Authors:  López-Vidal Yolanda; Ponce-de-León Sergio; Esquivel-Solís Hugo; Amieva-Fernández Rosa Isabel; Barreto-Zúñiga Rafael; Torre-Delgadillo Aldo; Castillo-Rojas Gonzalo
Journal:  BMC Cancer       Date:  2015-11-21       Impact factor: 4.430

5.  Previous Exposure to the Fish Parasite Anisakis as a Potential Risk Factor for Gastric or Colon Adenocarcinoma.

Authors:  Juan Carlos Garcia-Perez; Rosa Rodríguez-Perez; Araceli Ballestero; Jaime Zuloaga; Belen Fernandez-Puntero; Javier Arias-Díaz; María Luisa Caballero
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.